DRES-13. DUAL KINASE INHIBITION TO COMBAT EGFR-INHIBITOR RESISTANCE IN GLIOBLASTOMA

Glioblastoma (GBM) is an aggressive primary brain tumor with a poor survival rate. One of the most common molecular alterations seen in GBM is amplification and/or mutation of the Epidermal Growth Factor Receptor (EGFR), which has made it an attractive therapeutic target. However, several EGFR tyros...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Smithberger, Erin, Shelton, Abigail, Butler, Madison, Flores, Alex, Bash, Ryan, Angus, Steven, East, Michael, Sciaky, Noah, Dhruv, Harshil, Johnson, Gary, Berens, Michael, Furnari, Frank, Ryan Miller, C
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Drug Resistance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846925/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.300
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados